Increasing Quality of Life
Sativex is a cannabinod based oromucosal spray approved for the management of resistant MS spasticity, having demonstrated efficacy relieving spasticity and associated symptoms, such as spasms, cramps, pain, bladder dysfunction and sleep disorders and an appropriate tolerability profile, so MS spasticity patients can better develop their daily lives.
Please find here more about how to help your patients
Sativex Assistance Device
New data for moderate patients
SAVANT clinical trial sub-analysis from Dr. Meuth:
New research shows that Sativex® improves the mean MS spasticity score and pain score at week 12 compared to placebo – both in severe and moderate patients – regardless of initial EDSS, NRS score or MS spasticity duration.
Patient Support Materials
Ask the expert
Want to know more about Sativex? Click below to get in touch with Professor Tiina Rekand who will answer any questions you may have.
Sativex® is indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.